WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Roche

RocheHeadquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.

In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

www.roche.com.

Roche RSS Channel

Filters
List of articles in category Roche
Title Published Date
Roche named Dow Jones Sustainability Index leader in healthcare for third consecutive year 12 September 2011
Roche’s Tarceva receives European approval for first-line use in a genetically distinct type of lung cancer 06 September 2011
FDA approves Zelboraf and companion diagnostic for BRAF mutation-positive metastatic melanoma 18 August 2011
Roche's investigational treatment for asthma met its primary endpoint 08 August 2011
"Roche Continents" at the Salzburg Festival celebrates its five-year anniversary 28 July 2011
Roche to provide HIV/AIDS tests for Early Infant Diagnosis in South Africa 26 July 2011
Roche provides update from FDA hearing on Avastin for metastatic breast cancer 14 July 2011
Pivotal study showed vismodegib helped shrink tumours or heal lesions 21 June 2011
RoACTEMRA could change the current standard of treatment for people living with rheumatoid arthritis 30 May 2011
Roche to present significant progress in advanced skin, lung and ovarian cancers at ASCO 19 May 2011
New drug applications submitted in the United States and Europe for vemurafenib in advanced skin cancer 13 May 2011
Roche Group's first-quarter 2011 sales on track for full-year targets 18 April 2011
Roche announces positive pivotal Phase II results for Hedgehog Pathway Inhibitor 22 March 2011
Roche Annual General Meeting: dividend raised by 10% 01 March 2011
Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer 08 February 2011
The Roche Group posted solid overall results in 2010 02 February 2011
Roche personalized investigational medicine shows survival benefit in advanced skin cancer 19 January 2011
FDA grants supplemental approval for ACTEMRA 06 January 2011
Roche provides update on Avastin following reviews in Europe and the United States 16 December 2010
Rituxan/MabThera decreased the risk of needing later treatment with chemotherapy or radiotherapy by 80% 05 December 2010
  • Start
  • Prev
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • Next
  • End

Business & Industry

  • Pfizer to acquire Global Blood Therapeutics for $5.4 billion to enhance presence in rare hematology
  • Roche's subcutaneous formulation of Tecentriq demonstrates positive Phase III results
  • Bayer Consumer Health leaders propose new principles for science-led self-care
  • GSK signs agreement to support pandemic preparedness in Europe
  • Pfizer and BioNTech advance COVID-19 vaccine strategy with study start of next-generation vaccine candidate based on enhanced spike protein design

Research & Development

  • New method of nasal vaccine delivery could lead to better vaccines for HIV and COVID-19
  • Research identifies, exploits vulnerability in certain high-risk cancers
  • Scientists create long-acting injectable drug delivery system for tuberculosis
  • Treating cancer by sticking cells in place
  • Vitamin K prevents cell death: a new function for a long-known molecule
  • Disparities in United States COVID-19 vaccine distribution
  • New needle-free nasal vaccine shows promise for COVID-19

Conferences & Events

  • New approach to treatment of deadly kidney cancer
  • SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
  • Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
  • SMi's 22nd Annual Pain Therapeutics Conference
  • SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
  • SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
  • SMi's 3rd Annual AI in Drug Discovery Conference

Regulatory Affairs

  • FDA approves first systemic treatment for alopecia areata
  • FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
  • FDA limits use of Janssen COVID-19 vaccine to certain individuals
  • EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
  • FDA approves first generic of Symbicort to treat asthma and COPD
  1. You are here:  
  2. Home
  3. Roche
  4. Roche's subcutaneous formulation of Tecentriq demonstrates positive Phase III results

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2022. All Rights Reserved.